All HCM | Absence of pathogenic/likely pathogenic sarcomere gene mutation group | |||||
---|---|---|---|---|---|---|
Presence of sarcomere gene mutation group (n = 41) | Absence of sarcomere gene mutation group (n = 92) | P | Sarcomere VUS (n = 32) | Absence of sarcomere VUS (n = 60) | P | |
Age, years | 55.9 ± 13.5 | 59.6 ± 12.8 | 0.137 | 60.0 ± 12.5 | 59.4 ± 13.1 | 0.807 |
Women, n (%) | 16 (39) | 19 (21) | 0.026 | 8 (25) | 11 (18) | 0.589 |
Hypertension, n (%) | 281 (51) | 39 (42) | 0.345 | 15 (47) | 24 (40) | 0.658 |
Diabetes, n (%) | 7 (17) | 19 (21) | 0.631 | 7 (22) | 12 (20) | > 0.999 |
Persistent AF at echo, n (%) | 9 (22) | 7 (8) | 0.019 | 3 (9) | 4 (7) | 0.691 |
Apical HCM, n (%) | 13 (32) | 53 (58) | 0.006 | 14 (44) | 39 (65) | 0.076 |
Dynamic obstruction, n (%) | 7 (17) | 27 (29) | 0.134 | 10 (31) | 17 (28) | 0.813 |
LA volume index, mL/m2 | 41.2 ± 17.6 | 32.4 ± 11.3 | 0.005 | 35.2 ± 12.8 | 31.0 ± 10.2 | 0.109 |
Echo Doppler E/e’ | 15.4 ± 7.3 | 14.6 ± 5.3 | 0.454 | 16.3 ± 5.6 | 13.7 ± 5.0 | 0.036 |
Maximal thickness, mm | 19.9 ± 3.7 | 18.4 ± 3.6 | 0.032 | 18.5 ± 3.3 | 18.4 ± 3.8 | 0.911 |
5-year SCD risk (n = 83), % | 2.8 ± 1.5 | 1.9 ± 1.8 | 0.029 | 2.4 ± 3.0 | 1.7 ± 0.6 | 0.214 |